← Back to patent-cliff list
Chiauranib
Tier C — Watch / tradeChiauranib
Shenzhen Chipscreen Biosciences Co., Ltd.
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
-
Type
Targets：AURKB, VEGFR, PDGFR, KIT, CSF1R
Indications (approved)：胰腺导管癌, Ovarian cancer, Small cell lung cancer, Sarcoma, Non-Hodgkin lymphoma, 三阴性乳腺癌, Hepatocellular carcinoma, Solid tumour
Regional status
US
Phase II
2022-08-26
EU
-
China
Phase III
2021-03-05
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Chiauranib?
Approved indications include: 胰腺导管癌, Ovarian cancer, Small cell lung cancer, Sarcoma, Non-Hodgkin lymphoma, 三阴性乳腺癌, Hepatocellular carcinoma, Solid tumour.
When does the Chiauranib patent expire?
No public expiry year is available for Chiauranib yet; this page updates once verified.
How do I get a quote for Chiauranib intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-21